RxDoctor Payments Data

Ravi Bajpai, DO

Internal Medicine · Surprise, AZNPI 1083798334

Payments from drug & device makers

$3,471in general payments, 2019–2025

Across 167 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$383
  • AstraZeneca$302
  • Merck$220
  • Boston Scientific$216
  • Pfizer$212
  • Ultragenyx Pharmaceutical Inc.$175
  • plus $2K from 36 others

What the payments were for

  • Travel & lodging$191%
  • Food & beverage$3,41898%
  • Entertainment$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,471 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$92,560
Medicare patients
338
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate60$48,679
OzempicSemaglutide24$30,952
FarxigaDapagliflozin Propanediol19$23,702
EliquisApixaban20$18,967
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$15,621
TrulicityDulaglutide16$14,053
JardianceEmpagliflozin21$13,750
Breo ElliptaFluticasone/Vilanterol16$9,346
Fentanyl12$4,418
SymbicortBudesonide/Formoterol Fumarate16$4,263
Omeprazole255$3,759
Levothyroxine Sodium467$3,440
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,280
DexilantDexlansoprazole11$3,267
Atorvastatin Calcium378$3,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$220$48,67960 claims
Novo NordiskOzempic$73$30,95224 claims
AstraZenecaFarxiga, Symbicort$302$27,96535 claims
PfizerEliquis$212$18,96720 claims
Lilly USA, LLCTrulicity$64$14,05316 claims
Boehringer IngelheimJardiance$101$13,75021 claims
GSKBreo Ellipta$112$9,34616 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$15$3,26711 claims
AbbVieSynthroid$108$1,52330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →